Variable | Primary cohort | Validation cohort | ||
---|---|---|---|---|
Total N | N or Median (% or range) | Total N | N or Median (% or range) | |
Age | 587 | 75 (44–91) | 124 | 77 (48–90) |
Sex | 587 | 124 | ||
Female | 224 (38%) | 46 (37.1%) | ||
Male | 363 (62%) | 78 (62.9%) | ||
KPS | 581 | 124 | ||
≥ 90 | 117 (20%) | 54 (43.5%) | ||
70–80 | 395 (68%) | 62 (50.0%) | ||
≤ 60 | 69 (12%) | 8 (6.5%) | ||
Operable | 581 | 40 (7%) | 124 | 10 (8.1%) |
CCI | 587 | 3 (0–10) | 124 | 2 (0–9) |
CIRS | 587 | 5 (0–15) | 124 | 5 (0–16) |
Current/former smoker | 521 | 481 (92%) | ||
GOLD score | 580 | |||
1 | 97 (17%) | |||
2 | 240 (41%) | |||
3 | 144 (25%) | |||
4 | 37 (6%) | |||
Previous malignancy | 587 | 237 (40%) | ||
Previous lung cancer | 587 | 120 (20.4%) | ||
T stage | 587 | 124 | ||
T1 | 412 (70%) | 13 (10.5%) | ||
T2 | 147 (25%) | 55 (44.4%) | ||
T3 | 28 (5%) | 42 (33.9%) | ||
T4 | 0 (0%) | 14 (11.3%) | ||
Tumor diameter | 587 | 2.3 cm (0.7–7.7) | 124 | 4.6 cm (1.4–10.5) |
Pathology | 587 | 124 | ||
Unknown | 329 (56%) | |||
Squamous cell carcinoma | 94 (16%) | |||
Adenocarcinoma | 103 (18%) | |||
Large cell carcinoma | 51 (9%) | |||
Other | 10 (2%) | |||
Dose fractionation | 587 | 124 | ||
60 Gy/3 | 209 (36%) | |||
54 Gy/3 | 15 (3%) | |||
51 Gy/3 | 354 (60%) | |||
40 Gy/2 | 1 (0.2%) | |||
60 Gy/5 | 8 (1%) | |||
55 Gy/5 | 48 (38.4%) | |||
48 Gy/6 | 19 (15.2%) | |||
49 Gy/7 | 17 (13.7%) | |||
60 Gy/5 | 18 (14.4%) | |||
Other | 22 (17.6%) |